Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 3/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | ACHE | P22303 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18688200 | 0.86 | TYR (0.54) | TYRALDH1A1HTTCA12CA9 | |
| SCHEMBL3247865 | 0.86 | TYR (0.54) | TYRALDH1A1HTTCA12CA9 | |
| SCHEMBL11259884 | 0.86 | GRM5 (0.58) | TYRALDH1A1HTTCA12CA9 | |
| SCHEMBL6675068 | 0.85 | ALDH1A1 (0.61) | TYRALDH1A1HTTCA12CA9 | |
| SCHEMBL18954615 | 0.83 | ACHE (0.73) | TYRALDH1A1HTTCA12CA9 | |
| SCHEMBL6678039 | 0.83 | TYR (0.51) | TYRALDH1A1HTTCA12CA9 | |
| SCHEMBL540147 | 0.82 | ACHE (0.60) | TYRALDH1A1HTTCA12CA9 | |
| SCHEMBL540166 | 0.82 | GRM5 (0.52) | TYRALDH1A1HTTCA12CA9 | |
| SCHEMBL11259879 | 0.82 | GRM5 (0.60) | TYRALDH1A1HTTCA12CA9 | |
| SCHEMBL9196876 | 0.82 | MEN1 (0.50) | TYRALDH1A1HTTCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10106502-B2 | Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulators | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180148408-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-05-31 | — | — | US | disclosed |
| US-20180148408-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-05-31 | — | — | US | disclosed |
| US-20140256767-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | THE BROAD INSTITUTE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256767-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | THE BROAD INSTITUTE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256767-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | THE BROAD INSTITUTE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2013067036-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067036-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2009029625-A1 | 4- [HETEROCYCLYL-METHYL] -8-FLUORO-QUINOLIN-2-ONES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009029625-A1 | 4- [HETEROCYCLYL-METHYL] -8-FLUORO-QUINOLIN-2-ONES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| EP-0798292-B1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | CHUGAI SEIYAKUKABUSHIKI KAISHA (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-6534546-B1 | Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-18 | — | — | US | disclosed |
| EP-0798292-A1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 1997-10-01 | — | — | EP | disclosed |
| US-4362666-A | ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1982-12-07 | — | — | US | disclosed |
| US-4316900-A | Piperazinopyrrolobenzodiazepines | CIBA-GEIGY CORPORATION (US) | 1982-02-23 | — | — | US | disclosed |
| EP-0001585-B1 | PIPERAZINO-PYRROLOBENZODIAZEPINES, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1981-07-22 | — | — | EP | disclosed |
| EP-0001585-A1 | Piperazino-pyrrolobenzodiazepines, methods for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1979-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148408-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | KEAP1, NFE2L2, HMOX1 | TYR 1984/4885ALDH1A1 1021/4885HTT 1433/4885 |
| US-10106502-B2 | Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulators | KEAP1, NFE2L2, HMOX1 | TYR 1984/4885ALDH1A1 1021/4885HTT 1433/4885 |
| US-20140256767-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | KEAP1, NFE2L2, HMOX1 | TYR 1984/4885ALDH1A1 1021/4885HTT 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.